Herbreteau, G.; Vallée, A.; Knol, A.-C.; Théoleyre, S.; Quéreux, G.; Frénard, C.; Varey, E.; Hofman, P.; Khammari, A.; Dréno, B.;
et al. Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients. Cancers 2020, 12, 1871.
https://doi.org/10.3390/cancers12071871
AMA Style
Herbreteau G, Vallée A, Knol A-C, Théoleyre S, Quéreux G, Frénard C, Varey E, Hofman P, Khammari A, Dréno B,
et al. Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients. Cancers. 2020; 12(7):1871.
https://doi.org/10.3390/cancers12071871
Chicago/Turabian Style
Herbreteau, Guillaume, Audrey Vallée, Anne-Chantal Knol, Sandrine Théoleyre, Gaelle Quéreux, Cécile Frénard, Emilie Varey, Paul Hofman, Amir Khammari, Brigitte Dréno,
and et al. 2020. "Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients" Cancers 12, no. 7: 1871.
https://doi.org/10.3390/cancers12071871
APA Style
Herbreteau, G., Vallée, A., Knol, A.-C., Théoleyre, S., Quéreux, G., Frénard, C., Varey, E., Hofman, P., Khammari, A., Dréno, B., & Denis, M. G.
(2020). Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients. Cancers, 12(7), 1871.
https://doi.org/10.3390/cancers12071871